{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:05:42Z","timestamp":1792231542666,"version":"4.4.0"},"reference-count":100,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130103"],"award-info":[{"award-number":["82130103"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1804283"],"award-info":[{"award-number":["U1804283"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773570"],"award-info":[{"award-number":["81773570"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277110"],"award-info":[{"award-number":["22277110"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204209"],"award-info":[{"award-number":["82204209"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473761"],"award-info":[{"award-number":["82473761"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC0864700"],"award-info":[{"award-number":["2021YFC0864700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFE0202700"],"award-info":[{"award-number":["2022YFE0202700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021173","name":"Central Plains Scholars and Scientists Studio Fund","doi-asserted-by":"publisher","award":["2018002"],"award-info":[{"award-number":["2018002"]}],"id":[{"id":"10.13039\/501100021173","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023T160601"],"award-info":[{"award-number":["2023T160601"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Fluorinated nucleosides are an important class of modified nucleosides that have demonstrated therapeutic potential for treating various human diseases, especially viral infections and cancer. Many fluorinated nucleosides have advanced into clinical trials or have been approved by the FDA for use in patients. Among these fluorinated nucleosides, azvudine, developed by us, has been officially approved by the National Medical Products Administration for the treatment of coronavirus disease 2019 (COVID-19) and human immunodeficiency virus, indicating the therapeutic promise of fluorinated nucleosides. In view of the therapeutic promise of fluorinated nucleosides for antiviral and anticancer therapy, in this Review we will provide a comprehensive overview of well-established 2\u2032-fluorinated nucleosides approved for use in the market or those in clinical stages for antiviral and antitumor therapies, highlighting the drug discovery strategies, structure-activity relationship studies, mechanisms of action, and preclinical\/clinical studies and also discuss the challenges and future directions for nucleoside-based new drug discovery.<\/jats:p>","DOI":"10.1093\/nsr\/nwae331","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T04:29:49Z","timestamp":1727843389000},"source":"Crossref","is-referenced-by-count":26,"title":["2\u2032-Fluorinated nucleoside chemistry for new drug discovery: achievements and prospects"],"prefix":"10.1093","volume":"11","author":[{"given":"Yonggang","family":"Meng","sequence":"first","affiliation":[{"name":"College of Chemistry, Pingyuan Laboratory, State Key Laboratory of Antiviral Drugs, Zhengzhou University , Zhengzhou 450001 ,","place":["China"]},{"name":"School of Pharmaceutical Sciences, Zhengzhou University , Zhengzhou 450001 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Zhengzhou University , Zhengzhou 450001 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Liang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Antiviral Drugs, School of Chemistry and Chemical Engineering, Henan Normal University , Xinxiang 453007 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[{"name":"College of Chemistry, Pingyuan Laboratory, State Key Laboratory of Antiviral Drugs, Zhengzhou University , Zhengzhou 450001 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbiao","family":"Chang","sequence":"additional","affiliation":[{"name":"College of Chemistry, Pingyuan Laboratory, State Key Laboratory of Antiviral Drugs, Zhengzhou University , Zhengzhou 450001 ,","place":["China"]},{"name":"School of Pharmaceutical Sciences, Zhengzhou University , Zhengzhou 450001 ,","place":["China"]},{"name":"State Key Laboratory of Antiviral Drugs, School of Chemistry and Chemical Engineering, Henan Normal University , Xinxiang 453007 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"2024110817384236200_bib1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-020-00351-z","article-title":"Azvudine (FNC): a promising clinical candidate for COVID-19 treatment","volume":"5","author":"Yu","year":"2020","journal-title":"Sig Transduct Target Ther"},{"key":"2024110817384236200_bib2","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.2174\/1389450117666151209123751","article-title":"Nucleoside inhibitors of hepatitis C virus NS5B polymerase: a systematic review","volume":"17","author":"Xie","year":"2016","journal-title":"Curr Drug Targets"},{"key":"2024110817384236200_bib3","doi-asserted-by":"publisher","first-page":"104815","DOI":"10.1016\/j.antiviral.2020.104815","article-title":"HBV replication inhibitors","volume":"179","author":"Pierra Rouviere","year":"2020","journal-title":"Antiviral Res"},{"key":"2024110817384236200_bib4","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/194985a0","article-title":"Anti-viral activities of several iodinated pyrimidine deoxyribonucleosides","volume":"194","author":"Perkins","year":"1962","journal-title":"Nature"},{"key":"2024110817384236200_bib5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1039\/B610213C","article-title":"Fluorine in medicinal chemistry","volume":"37","author":"Purser","year":"2008","journal-title":"Chem Soc Rev"},{"key":"2024110817384236200_bib6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/cancers10070240","article-title":"Nucleobase and nucleoside analogues: resistance and re-sensitisation at the level of pharmacokinetics, pharmacodynamics and metabolism","volume":"10","author":"Tsesmetzis","year":"2018","journal-title":"Cancers"},{"key":"2024110817384236200_bib7","doi-asserted-by":"publisher","first-page":"e202200066","DOI":"10.1002\/tcr.202200066","article-title":"Strategies for the synthesis of fluorinated nucleosides, nucleotides and oligonucleotides","volume":"22","author":"Shet","year":"2022","journal-title":"Chem Rec"},{"key":"2024110817384236200_bib8","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","article-title":"Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design","volume":"61","author":"Meanwell","year":"2018","journal-title":"J Med Chem"},{"key":"2024110817384236200_bib9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/00304948.2017.1290994","article-title":"Synthesis of antitumor fluorinated pyrimidine nucleosides","volume":"49","author":"Ferraboschi","year":"2017","journal-title":"Org Prep Proced Int"},{"key":"2024110817384236200_bib10","doi-asserted-by":"publisher","first-page":"11282","DOI":"10.1021\/acs.jmedchem.3c00761","article-title":"4\u2032-Ethynyl-2\u2032-deoxy-2\u2032-\u03b2-fluoro-2-fluoroadenosine: a highly potent and orally available clinical candidate for the treatment of HIV-1 infection","volume":"66","author":"Hou","year":"2023","journal-title":"J Med Chem"},{"key":"2024110817384236200_bib11","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1021\/ja01485a036","article-title":"Synthesis of 2\u2032-deoxy-2\u2032-fluorouridine","volume":"83","author":"Codington","year":"1961","journal-title":"J Am Chem Soc"},{"key":"2024110817384236200_bib12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1021\/jm00059a007","article-title":"Uniformly modified 2\u2032-deoxy-2\u2032-fluoro-phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets","volume":"36","author":"Kawasaki","year":"1993","journal-title":"J Med Chem"},{"key":"2024110817384236200_bib13","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1128\/AAC.48.2.651-654.2004","article-title":"Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2\u2032-deoxy-2\u2032-fluorocytidine","volume":"48","author":"Stuyver","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110817384236200_bib14","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1021\/jm0502788","article-title":"Design, synthesis, and antiviral activity of 2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine, a potent inhibitor of hepatitis C virus replication","volume":"48","author":"Clark","year":"2005","journal-title":"J Med Chem"},{"key":"2024110817384236200_bib15","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3390\/ijms22041581","article-title":"Comparison of antiviral activity of gemcitabine with 2\u2032-fluoro-2\u2032-deoxycytidine and combination therapy with remdesivir against SARS-CoV-2","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024110817384236200_bib16","first-page":"1838","article-title":"Studies on the growth inhibition and metabolism of 2\u2032-deoxy-2\u2032-fluorocytidine in cultured human lymphoblasts","volume":"34","author":"Brox","year":"1974","journal-title":"Cancer Res"},{"key":"2024110817384236200_bib17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1128\/AAC.00400-06","article-title":"Mechanism of activation of \u03b2-D-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase","volume":"51","author":"Murakami","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110817384236200_bib18","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1128\/AAC.01184-07","article-title":"The mechanism of action of \u03b2-D-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine involves a second metabolic pathway leading to \u03b2-D-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methyluridine 5\u2032-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase","volume":"52","author":"Murakami","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110817384236200_bib19","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1128\/AAC.00193-07","article-title":"Pharmacokinetics of the antiviral agent \u03b2-D-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine in rhesus monkeys","volume":"51","author":"Asif","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110817384236200_bib20","doi-asserted-by":"publisher","first-page":"S224","DOI":"10.1016\/S0168-8278(07)62188-6","article-title":"Inhibition of HCV replication by PSI-6130: mechanism of biochemical activation and inhibition","volume":"46","author":"Furman","year":"2007","journal-title":"J Hepatol"},{"key":"2024110817384236200_bib21","article-title":"Antiviral nucleosides","author":"Chun","year":"2007"},{"key":"2024110817384236200_bib22","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","article-title":"Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"376","author":"Gane","year":"2010","journal-title":"Lancet"},{"key":"2024110817384236200_bib23","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1086\/656774","article-title":"RG7128 alone or in combination with pegylated interferon-\u03b12a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients","volume":"202","author":"Le Pogam","year":"2010","journal-title":"J Infect Dis"},{"key":"2024110817384236200_bib24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/9780470929353.ch21","article-title":"Discovery and development of PSI-6130\/RG7128","volume-title":"Antiviral Drugs: from Basic Discovery Through Clinical Trials","author":"Furman","year":"2011"},{"key":"2024110817384236200_bib25","doi-asserted-by":"publisher","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a \u03b2-D-2\u2032-deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J Med Chem"},{"key":"2024110817384236200_bib26","doi-asserted-by":"publisher","first-page":"34337","DOI":"10.1074\/jbc.M110.161802","article-title":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977","volume":"285","author":"Murakami","year":"2010","journal-title":"J Biol Chem"},{"key":"2024110817384236200_bib27","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1586\/14787210.2013.855126","article-title":"Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection","volume":"11","author":"Rodr\u00edguez-Torres","year":"2013","journal-title":"Expert Rev Anti Infect"},{"key":"2024110817384236200_bib28","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/apt.12601","article-title":"Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection","volume":"39","author":"Koff","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2024110817384236200_bib29","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/j.bmcl.2005.12.002","article-title":"Synthesis and antiviral activity of 2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication","volume":"16","author":"Clark","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"2024110817384236200_bib30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1021\/ml100209f","article-title":"Discovery of PSI-353661, a novel purine nucleotide prodrug for the treatment of HCV infection","volume":"2","author":"Chang","year":"2011","journal-title":"ACS Medicinal Chem Lett"},{"key":"2024110817384236200_bib31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.antiviral.2011.05.003","article-title":"Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661","volume":"91","author":"Furman","year":"2011","journal-title":"Antiviral Res"},{"key":"2024110817384236200_bib32","doi-asserted-by":"publisher","first-page":"7376","DOI":"10.1016\/j.bmcl.2010.10.035","article-title":"2\u2032-deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methyl 3\u2032,5\u2032-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938","volume":"20","author":"Reddy","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"2024110817384236200_bib33","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1128\/AAC.00530-12","article-title":"Metabolic activation of the anti-hepatitis C virus nucleotide prodrug PSI-352938","volume":"56","author":"Niu","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110817384236200_bib34","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1128\/AAC.00032-11","article-title":"Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of \u03b2-D-2\u2032-deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methylguanosine","volume":"55","author":"Lam","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110817384236200_bib35","doi-asserted-by":"publisher","first-page":"12334","DOI":"10.1128\/JVI.05639-11","article-title":"Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA","volume":"85","author":"Lam","year":"2011","journal-title":"J Virol"},{"key":"2024110817384236200_bib36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1517\/13543784.2015.982274","article-title":"Discontinued drugs in 2012\u20132013: hepatitis C virus infection","volume":"24","author":"Gentile","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"2024110817384236200_bib37","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1002\/cncr.21005","article-title":"The role of clofarabine in hematologic and solid malignancies\u2013development of a next-generation nucleoside analog","volume":"103","author":"Faderl","year":"2005","journal-title":"Cancer"},{"key":"2024110817384236200_bib38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrd1724","article-title":"Clofarabine","volume":"4","author":"Pui","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"2024110817384236200_bib39","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s13361-019-02222-6","article-title":"Structures and relative glycosidic bond stabilities of protonated 2\u2032-fluoro-substituted purine nucleosides","volume":"30","author":"Devereaux","year":"2019","journal-title":"J Am Soc Mass Spectrom"},{"key":"2024110817384236200_bib40","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1073\/pnas.81.7.2232","article-title":"Antileukemic and immunosuppressive activity of 2-chloro-2\u2032-deoxyadenosine","volume":"81","author":"Carson","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024110817384236200_bib41","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1200\/JCO.2003.04.031","article-title":"Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers","volume":"21","author":"Kantarjian","year":"2003","journal-title":"J Clin Oncol"},{"key":"2024110817384236200_bib42","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","article-title":"Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia","volume":"102","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"2024110817384236200_bib43","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1128\/AAC.17.5.803","article-title":"2\u2032-fluoro-5-iodo-aracytosine, a potent and selective anti-herpesvirus agent","volume":"17","author":"Lopez","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110817384236200_bib44","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1128\/AAC.28.2.252","article-title":"Antiviral activity of 2\u2032-deoxy-2\u2032-fluoro-beta-D-arabinofuranosyl-5-iodocytosine against human cytomegalovirus in human skin fibroblasts","volume":"28","author":"Colacino","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110817384236200_bib45","first-page":"5006","article-title":"Phase I evaluation of 2\u2032-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in immunosuppressed patients with herpesvirus infection","volume":"43","author":"Young","year":"1983","journal-title":"Cancer Res"},{"key":"2024110817384236200_bib46","volume-title":"Review of the Fialuridine (FIAU) Clinical Trials","author":"Institute of Medicine (US)","year":"1995"},{"key":"2024110817384236200_bib47","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0166-3542(84)90001-9","article-title":"Physical and biological consequences of incorporation of antiviral agents into virus DNA","volume":"4","author":"Prusoff","year":"1984","journal-title":"Antiviral Res"},{"key":"2024110817384236200_bib48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1128\/AAC.29.1.77","article-title":"Activities of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2","volume":"29","author":"Schinazi","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110817384236200_bib49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00002018-199717010-00001","article-title":"Mitochondrial injury. Lessons from the fialuridine trial","volume":"17","author":"Honkoop","year":"1997","journal-title":"Drug Saf"},{"key":"2024110817384236200_bib50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0166-3542(94)90032-9","article-title":"The in vitro anti-hepatitis B virus activity of FIAU [1-(2\u2032-deoxy-2\u2032-fluoro-1-\u03b2-D-arabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell","volume":"23","author":"Staschke","year":"1994","journal-title":"Antiviral Res"},{"key":"2024110817384236200_bib51","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJM199510263331702","article-title":"Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B","volume":"333","author":"McKenzie","year":"1995","journal-title":"N Engl J Med"},{"key":"2024110817384236200_bib52","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1073\/pnas.93.8.3592","article-title":"Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts","volume":"93","author":"Lewis","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024110817384236200_bib53","doi-asserted-by":"publisher","first-page":"e1001628","DOI":"10.1371\/journal.pmed.1001628","article-title":"Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing","volume":"11","author":"Xu","year":"2014","journal-title":"PLoS Med"},{"key":"2024110817384236200_bib54","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/0042-6822(62)90058-2","article-title":"Cure of vaccinia infection by 5-iodo-2\u2032-deoxyuridine","volume":"18","author":"Kaufman","year":"1962","journal-title":"Virology"},{"key":"2024110817384236200_bib55","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/197767a0","article-title":"Suppression of infections resulting from a deoxyribonucleic acid virus (vaccinia) by systemic adminstration of 5-iodo-2\u2032-deoxyuridine","volume":"197","author":"Calabresi","year":"1963","journal-title":"Nature"},{"key":"2024110817384236200_bib56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1021\/jm00187a005","article-title":"Nucleosides. 110. Synthesis and antiherpes virus activity of some 2\u2032-fluoro-2\u2032-deoxyarabinofuranosylpyrimidine nucleosides","volume":"22","author":"Watanabe","year":"1979","journal-title":"J Med Chem"},{"key":"2024110817384236200_bib57","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1128\/AAC.39.4.979","article-title":"Use of 2\u2032-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus","volume":"39","author":"Chu","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110817384236200_bib58","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1128\/AAC.42.4.833","article-title":"Unique metabolism of a novel antiviral L-nucleoside analog, 2\u2032-fluoro-5-methyl-\u03b2-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase","volume":"42","author":"Liu","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110817384236200_bib59","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1021\/jm960098l","article-title":"Structure\u2013activity relationships of 1-(2-deoxy-2-fluoro-\u03b2-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents","volume":"39","author":"Ma","year":"1996","journal-title":"J Med Chem"},{"key":"2024110817384236200_bib60","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1586\/14787210.4.4.549","article-title":"Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo","volume":"4","author":"Korba","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024110817384236200_bib61","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/hep.20257","article-title":"A Phase II dose-escalating trial of clevudine in patients with chronic hepatitis B","volume":"40","author":"Marcellin","year":"2004","journal-title":"Hepatology"},{"key":"2024110817384236200_bib62","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1021\/acs.jmedchem.0c00940","article-title":"Mechanistic insight into antiretroviral potency of 2\u2032-deoxy-2\u2032-\u03b2-fluoro-4\u2032-azidocytidine (FNC) with a long-lasting effect on HIV-1 prevention","volume":"63","author":"Sun","year":"2020","journal-title":"J Med Chem"},{"key":"2024110817384236200_bib63","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s40265-016-0633-9","article-title":"Trifluridine\/tipiracil: a review in metastatic colorectal cancer","volume":"76","author":"Burness","year":"2016","journal-title":"Drugs"},{"key":"2024110817384236200_bib64","first-page":"100321","article-title":"The first Chinese oral anti-COVID-19 drug azvudine launched","volume":"3","author":"Yu","year":"2022","journal-title":"Innovation (Camb)"},{"key":"2024110817384236200_bib65","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1002\/cjoc.202300361","article-title":"A nearly 20-year journey to success of azvudine for antiviral therapy","volume":"41","author":"Yu","year":"2023","journal-title":"Chinese J Chem"},{"key":"2024110817384236200_bib66","article-title":"2\u2032-Fluoro-4\u2032-substituted-nucleoside analogue and use thereof","author":"Chang","year":"2009"},{"key":"2024110817384236200_bib67","article-title":"Crystal form, preparation and the application of 4\u2032-substituted nucleosides","author":"Chang","year":"2019"},{"key":"2024110817384236200_bib68","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.1016\/j.bmcl.2011.09.040","article-title":"Synthesis and anti-HIV-1 activity of 4-substituted-7-(2\u2032-deoxy-2\u2032-fluoro-4\u2032-azido-\u03b2-D-ribofuranosyl) pyrrolo[2,3-d]pyrimidine analogues","volume":"21","author":"Guo","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"2024110817384236200_bib69","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1016\/j.ejmech.2011.06.020","article-title":"Synthesis of new 2\u2032-deoxy-2\u2032-fluoro-4\u2032-azido nucleoside analogues as potent anti-HIV agents","volume":"46","author":"Wang","year":"2011","journal-title":"Eur J Med Chem"},{"key":"2024110817384236200_bib70","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41392-021-00835-6","article-title":"Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients","volume":"6","author":"Zhang","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"2024110817384236200_bib71","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1021\/jm801595c","article-title":"The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4\u2032-azidocytidine against hepatitis C virus replication: the discovery of 4\u2032-azido-2\u2032-deoxy-2\u2032-fluorocytidine and 4\u2032-azido-2\u2032-dideoxy-2\u2032,2\u2032-difluorocytidine","volume":"52","author":"Smith","year":"2009","journal-title":"J Med Chem"},{"key":"2024110817384236200_bib72","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3851\/IMP2292","article-title":"Novel nucleoside analogue FNC is effective against both wild-type and lamivudine-resistant HBV clinical isolates","volume":"17","author":"Zhou","year":"2012","journal-title":"Antivir Ther"},{"key":"2024110817384236200_bib73","doi-asserted-by":"publisher","first-page":"6829","DOI":"10.7314\/APJCP.2014.15.16.6829","article-title":"FNC, a novel nucleoside analogue, blocks invasion of aggressive non-Hodgkin lymphoma cell lines via inhibition of the wnt\/\u03b2-catenin signaling pathway","volume":"15","author":"Zhang","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"2024110817384236200_bib74","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.bcp.2011.01.001","article-title":"FNC, a novel nucleoside analogue inhibits cell proliferation and tumor growth in a variety of human cancer cells","volume":"81","author":"Wang","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"2024110817384236200_bib75","doi-asserted-by":"publisher","first-page":"e0174112","DOI":"10.1371\/journal.pone.0174112","article-title":"FNC efficiently inhibits mantle cell lymphoma growth","volume":"12","author":"Zhang","year":"2017","journal-title":"PLoS One"},{"key":"2024110817384236200_bib76","doi-asserted-by":"publisher","first-page":"6254","DOI":"10.1128\/AAC.01703-13","article-title":"Effects of substitutions at the 4\u2032 and 2 positions on the bioactivity of 4\u2032-ethynyl-2-fluoro-2\u2032-deoxyadenosine","volume":"57","author":"Kirby","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110817384236200_bib77","article-title":"2\u2032-fluorine-4\u2032-substituted-nucleoside analogues, preparation methods and uses thereof","author":"Chang","year":"2010"},{"key":"2024110817384236200_bib78","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1073\/pnas.89.7.2970","article-title":"Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2\u2032-arabino-fluoro-2\u2032-deoxyadenosine","volume":"89","author":"Carson","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024110817384236200_bib79","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1021\/jo00246a002","article-title":"Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2\u2032-difluoro-D-ribofuranosyl nucleosides","volume":"53","author":"Hertel","year":"1988","journal-title":"J Org Chem"},{"key":"2024110817384236200_bib80","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/0006-2952(93)90444-2","article-title":"Kinetic studies on 2\u2032,2\u2032-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase","volume":"45","author":"Bouffard","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"2024110817384236200_bib81","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1124\/mol.104.006098","article-title":"Phosphorylation of cytidine, deoxycytidine, and their analog monophosphates by human UMP\/CMP kinase is differentially regulated by ATP and magnesium","volume":"67","author":"Hsu","year":"2005","journal-title":"Mol Pharmacol"},{"key":"2024110817384236200_bib82","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.2174\/092986712799320682","article-title":"Gemcitabine: a critical nucleoside for cancer therapy","volume":"19","author":"Gesto","year":"2012","journal-title":"Curr Med Chem"},{"key":"2024110817384236200_bib83","first-page":"6110","article-title":"Action of 2\u2032,2\u2032-difluorodeoxycytidine on DNA synthesis","volume":"51","author":"Huang","year":"1991","journal-title":"Cancer Res"},{"key":"2024110817384236200_bib84","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/0006-2952(93)90566-F","article-title":"2\u2032,2\u2032-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines","volume":"46","author":"Ruiz van Haperen","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"2024110817384236200_bib85","first-page":"4024","article-title":"Comparison of the cellular pharmacokinetics and toxicity of 2\u2032,2\u2032-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine","volume":"48","author":"Heinemann","year":"1988","journal-title":"Cancer Res"},{"key":"2024110817384236200_bib86","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/genes13030466","article-title":"Recent development of prodrugs of gemcitabine","volume":"13","author":"Pandit","year":"2022","journal-title":"Genes"},{"key":"2024110817384236200_bib87","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/0006-2952(95)02402-6","article-title":"Regulation of phosphorylation of deoxycytidine and 2\u2032,2\u2032-difluorodeoxycytidine (gemcitabine); effects of cytidine 5\u2032-triphosphate and uridine 5\u2032-triphosphate in relation to chemosensitivity for 2\u2032,2\u2032-difluorodeoxycytidine","volume":"51","author":"Ruiz van Haperen","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"2024110817384236200_bib88","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1158\/1078-0432.CCR-07-4885","article-title":"Modulation of gemcitabine (2\u2032,2\u2032-difluoro-2\u2032-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine","volume":"14","author":"Beumer","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2024110817384236200_bib89","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1021\/jm901181h","article-title":"Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine","volume":"52","author":"Bender","year":"2009","journal-title":"J Med Chem"},{"key":"2024110817384236200_bib90","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s10637-015-0207-9","article-title":"Phase 1b study of the oral gemcitabine \u2018Pro-drug\u2019 LY2334737 in combination with capecitabine in patients with advanced solid tumors","volume":"33","author":"Infante","year":"2015","journal-title":"Invest New Drug"},{"key":"2024110817384236200_bib91","doi-asserted-by":"publisher","first-page":"8159","DOI":"10.1038\/s41598-020-65152-4","article-title":"Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications","volume":"10","author":"Sun","year":"2020","journal-title":"Sci Rep"},{"key":"2024110817384236200_bib92","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s10637-009-9377-7","article-title":"Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models","volume":"29","author":"Bergman","year":"2011","journal-title":"Invest New Drug"},{"key":"2024110817384236200_bib93","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s10637-013-9925-z","article-title":"Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors","volume":"31","author":"Stuurman","year":"2013","journal-title":"Invest New Drug"},{"key":"2024110817384236200_bib94","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00280-015-2846-0","article-title":"A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours","volume":"76","author":"Venugopal","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2024110817384236200_bib95","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.pan.2014.07.003","article-title":"A Phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression","volume":"14","author":"Li","year":"2014","journal-title":"Pancreatology"},{"key":"2024110817384236200_bib96","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1021\/jm401853a","article-title":"Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development","volume":"57","author":"Slusarczyk","year":"2014","journal-title":"J Med Chem"},{"key":"2024110817384236200_bib97","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12032-020-01386-6","article-title":"NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials","volume":"37","author":"Kapacee","year":"2020","journal-title":"Med Oncol"},{"key":"2024110817384236200_bib98","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1128\/AAC.01215-07","article-title":"Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131","volume":"52","author":"Cihlar","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024110817384236200_bib99","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1016\/j.bmc.2010.03.041","article-title":"Discovery of GS-9131: design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148","volume":"18","author":"Mackman","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"2024110817384236200_bib100","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14728214.2018.1474202","article-title":"Emerging reverse transcriptase inhibitors for HIV-1 infection","volume":"23","author":"Rai","year":"2018","journal-title":"Expert Opin Emerg Drugs"}],"container-title":["National Science Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nsr\/advance-article-pdf\/doi\/10.1093\/nsr\/nwae331\/59491993\/nwae331.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nsr\/article-pdf\/11\/10\/nwae331\/60542765\/nwae331.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nsr\/article-pdf\/11\/10\/nwae331\/60542765\/nwae331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T17:39:11Z","timestamp":1731087551000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nsr\/article\/doi\/10.1093\/nsr\/nwae331\/7804363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":100,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/nsr\/nwae331","relation":{},"ISSN":["2095-5138","2053-714X"],"issn-type":[{"value":"2095-5138","type":"print"},{"value":"2053-714X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,9,18]]},"article-number":"nwae331"}}